Opaleye Management’s Fulcrum Therapeutics FULC Stock Holding History

Opaleye Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-285,000	Closed	-$1.77M	–	48
2024 Q2	$1.77M	Buy	285,000 +155,000	+119%	+$1.17M	0.4%	43
2024 Q1	$1.23M	Hold	130,000	–	–	0.27%	45
2023 Q4	$878K	Buy	+130,000	New	+$577K	0.23%	44
2023 Q3	–	Sell	-143,600	Closed	-$474K	–	46
2023 Q2	$474K	Buy	+143,600	New	+$422K	0.11%	46
2022 Q2	–	Sell	-136,000	Closed	-$3.22M	–	49
2022 Q1	$3.22M	Buy	+136,000	New	+$1.92M	1%	28
2021 Q1	–	Sell	-88,300	Closed	-$1.03M	–	61
2020 Q4	$1.03M	Sell	88,300 -363,700	-80%	-$4.11M	0.14%	53
2020 Q3	$3.58M	Buy	+452,000	New	+$5.44M	0.7%	37

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Opaleye Management's FULC Position: Q3 2024 in Review

Opaleye Management sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 285,000 shares — an estimated $1.77M sold.

Opaleye Management first reported a position in FULC in Q3 2020 and held it in 7 quarters. The position peaked at $3.58M in Q3 2020. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

Opaleye Management reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
Opaleye Management sold 285,000 Fulcrum Therapeutics shares in Q3 2024, an estimated $1.77M.
Opaleye Management first reported a position in Fulcrum Therapeutics in Q3 2020 and held it in 7 quarters.
Opaleye Management's Fulcrum Therapeutics position peaked at $3.58M in Q3 2020.
130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.